Diclogen® Plus (Gel) Instructions for Use
Marketing Authorization Holder
Agio Pharmaceuticals, Ltd. (India)
ATC Code
M02AX10 (Other drugs)
Active Substances
Methyl salicylate (Ph.Eur.)
Menthol (Ph.Eur.)
Diclofenac (Rec.INN)
Dosage Form
| Diclogen® Plus | Gel for external use: tubes 30 g or 50 g |
Dosage Form, Packaging, and Composition
Gel for external use from almost white to light yellow, homogeneous, with a characteristic odor.
| 1 g | |
| Diclofenac diethylamine | 11.6 mg, |
| Equivalent to diclofenac sodium content | 10 mg |
| Methyl salicylate | 100 mg |
| Menthol (levomenthol) | 50 mg |
Excipients: linseed oil (first cold pressed linseed oil) – 30 mg, carbomer 940 – 20 mg, trolamine – 30 mg, propylene glycol – 25 mg, isopropyl alcohol – 25 mg, benzyl alcohol – 10 mg, methylparaben – 2 mg, propylparaben – 2 mg, liquid paraffin (light liquid paraffin) – 20 mg, white soft paraffin – 20 mg, macrogol 40 glyceryl hydroxystearate (polyoxyl 40 hydrogenated castor oil) – 45 mg, purified water – up to 1 g.
30 g – aluminum tubes (1) – cardboard boxes.
50 g – aluminum tubes (1) – cardboard boxes.
Clinical-Pharmacological Group
NSAIDs for external use
Pharmacotherapeutic Group
Topical anti-inflammatory agent
Pharmacological Action
Combined anti-inflammatory drug.
Diclofenac and Methyl salicylate are non-steroidal anti-inflammatory drugs (NSAIDs). They exert local analgesic, anti-inflammatory, and anti-exudative effects. The mechanism of action is due to the suppression of prostaglandin synthesis. When applied topically, they reduce pain and inflammation in the joints, morning stiffness and joint swelling, and help increase the range of motion. Menthol (racemic menthol) causes irritation of nerve endings, exerts a local distracting and mild analgesic effect, and causes a feeling of coolness at the site of application.
Pharmacokinetics
When applied externally, diclofenac and Methyl salicylate are absorbed and penetrate into the subcutaneous tissue, muscle tissue, and joint capsule.
Indications
For the symptomatic therapy of musculoskeletal system diseases
- Rheumatoid arthritis;
- Psoriatic arthritis;
- Ankylosing spondylitis;
- Osteoarthritis of peripheral joints and spine;
- Rheumatic soft tissue lesions;
- Muscle pain of rheumatic and non-rheumatic origin;
- Traumatic soft tissue injuries.
ICD codes
| ICD-10 code | Indication |
| M05 | Seropositive rheumatoid arthritis |
| M07 | Psoriatic and enteropathic arthropathies |
| M15 | Polyosteoarthritis |
| M19.9 | Unspecified arthrosis |
| M45 | Ankylosing spondylitis |
| M47 | Spondylosis |
| M65 | Synovitis and tenosynovitis |
| M70 | Soft tissue disorders related to use, overuse, and pressure |
| M71 | Other bursopathies |
| M79.0 | Unspecified rheumatism |
| M79.1 | Myalgia |
| T14.0 | Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect) |
| T14.3 | Dislocation, sprain and strain of joint and ligament of unspecified body region |
| ICD-11 code | Indication |
| EH92 | Dermatoses provoked by friction or mechanical impact |
| EH92.1 | Blister due to friction |
| FA05 | Polyosteoarthritis |
| FA0Z | Osteoarthritis, unspecified |
| FA20.0 | Seropositive rheumatoid arthritis |
| FA21.Z | Psoriatic arthritis, unspecified |
| FA27.2 | Palindromic rheumatism |
| FA8Z | Degenerative disease of spine, unspecified |
| FA92.0Z | Ankylosing spondylitis, unspecified |
| FB40.Z | Tenosynovitis, unspecified |
| FB50.1 | Bursitis associated with use, overuse or pressure |
| FB50.Z | Bursitis, unspecified |
| FB51.3 | Fibroblastic rheumatism |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| FB56.2 | Myalgia |
| ND56.0 | Superficial injury of unspecified body region |
| ND56.3 | Dislocation, sprain or strain of unspecified body region |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Externally.
Adults and children over 12 years apply the drug in a thin layer over the focus of inflammation 3-4 times a day and rub in gently. The required amount of the drug depends on the size of the painful area. A single dose of the drug is 2-4 g (comparable in volume to the size of a large cherry).
Children from 6 to 12 years use no more than 2 times a day, a single dose of the drug up to 2 g.
After applying the drug, hands must be washed.
The duration of treatment depends on the indications and the observed effect. After 2 weeks of using the drug, a doctor should be consulted.
Adverse Reactions
Local reactions eczema, photosensitivity, contact dermatitis (itching, redness, swelling of the treated skin area, papules, vesicles, peeling).
Systemic reactions generalized skin rash, urticaria, angioedema, bronchospastic reactions.
Contraindications
- History of bronchospasm, rhinitis, urticaria after taking acetylsalicylic acid or another NSAID;
- Pregnancy (III trimester);
- Lactation period;
- Children’s age (under 6 years);
- Violation of the integrity of the skin at the intended site of application;
- Hypersensitivity to diclofenac or other components of the drug, to acetylsalicylic acid or other NSAIDs.
With caution: hepatic porphyria (exacerbation), erosive and ulcerative lesions of the gastrointestinal tract, severe impairment of liver and kidney function, chronic heart failure, elderly age, bronchial asthma, pregnancy (I and II trimester).
Use in Pregnancy and Lactation
The drug is contraindicated in the third trimester of pregnancy. The issue of using the drug in the first and second trimesters of pregnancy is decided individually. Due to the lack of experience with the use of Diclogen Plus during lactation, the use of the drug during this period is not recommended.
Use in Hepatic Impairment
With caution: hepatic porphyria (exacerbation), severe liver dysfunction.
Use in Renal Impairment
With caution: severe renal impairment.
Pediatric Use
Contraindicated in children under 6 years of age.
Geriatric Use
With caution: elderly age.
Special Precautions
The drug should be applied only to intact skin, avoiding contact with open wounds. After application, an occlusive dressing should not be applied. Avoid getting the drug in the eyes and on mucous membranes.
Overdose
When applied externally in recommended doses, the extremely low systemic absorption of the active components of the drug makes overdose practically impossible.
Drug Interactions
Diclofenac may enhance the effect of drugs that cause photosensitivity. Clinically significant interaction with other drugs has not been described.
Storage Conditions
The drug should be stored out of the reach of children at a temperature not exceeding 25°C (77°F).
Shelf Life
Shelf life – 3 years. Do not use after the expiration date.
Dispensing Status
The drug is available without a prescription.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer